Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2021-08-26 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
独立董事对第四届董事会第三十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding specific matters discussed in a board meeting, including related party transactions, use of raised funds, external guarantees, and compliance with regulations. It references a specific board meeting date and discusses governance and compliance issues rather than presenting financial statements or full financial results. The document length is short (1290 characters), and it does not contain comprehensive financial data or detailed financial analysis. It is not an announcement of voting results or a proxy solicitation. The content aligns with Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on governance and compliance issues.
2021-08-26 Chinese
董事会决议公告
Report Publication Announcement Classification · 95% confidence The document is an announcement of the board meeting resolution approving the 2021 half-year report and its summary. It states that the half-year report and summary have been reviewed and comply with relevant laws and regulations. The document is short (753 characters) and refers readers to the official disclosure website for the full half-year report and summary. It does not contain the actual financial statements or substantive financial data itself, but rather announces the approval and availability of the interim report. According to the 'Menu vs Meal' rule, this is a report publication announcement rather than the interim report itself.
2021-08-26 Chinese
2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "天津瑞普生物技术股份有限公司 2021 年半年度报告全文" which translates to "Tianjin Ringpu Biotechnology Co., Ltd. 2021 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company business overview, financial indicators, and other comprehensive information typical of a semi-annual or interim financial report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes financial figures for the half-year period, management commentary, risk disclosures, and detailed operational data. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2021
2021-08-26 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021 半年度报告摘要' which translates to '2021 Half-Year Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period ending June 30, 2021. It also discusses business segments, operational highlights, and shareholder information. The presence of comprehensive financial metrics and business analysis for a half-year period indicates this is an Interim / Quarterly Report. The document length is 4426 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-26 Chinese
监事会决议公告
Report Publication Announcement Classification · 95% confidence The document is a resolution announcement from the Supervisory Board meeting approving the 2021 semi-annual report and its summary. It states that the report complies with relevant laws and accurately reflects the company's operating status for the first half of 2021. However, the actual semi-annual report is not included in this document; instead, it references that the report and summary are disclosed on the official regulatory website and in newspapers. The document length is short (736 characters), and it serves as an announcement of the report's approval and disclosure rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR).
2021-08-26 Chinese
关于公司申请向特定对象发行股票发行注册环节反馈意见落实函回复的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the company's response to feedback from the China Securities Regulatory Commission (CSRC) and Shenzhen Stock Exchange (SZSE) about the registration process for a specific private placement of shares. It discusses the company's reply to regulatory feedback and the ongoing registration process, emphasizing that the issuance is subject to CSRC approval and contains a caution about investment risks. The document is short (714 characters) and serves as a regulatory update on the capital raising process rather than the actual issuance or detailed financial data. It does not contain financial statements or detailed report content but is an announcement related to capital issuance and regulatory compliance. Therefore, it fits best under Capital/Financing Update (CAP).
2021-08-13 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.